Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.70 Insider Own43.02% Shs Outstand25.51M Perf Week-3.04%
Market Cap534.09M Forward P/E- EPS next Y-3.23 Insider Trans-0.20% Shs Float17.35M Perf Month-0.45%
Income-63.78M PEG- EPS next Q-0.70 Inst Own42.31% Short Float10.73% Perf Quarter18.83%
Sales0.00M P/S- EPS this Y-5.51% Inst Trans5.92% Short Ratio8.45 Perf Half Y75.05%
Book/sh5.48 P/B3.20 EPS next Y-13.68% ROA-34.76% Short Interest1.86M Perf Year78.98%
Cash/sh5.93 P/C2.96 EPS next 5Y29.00% ROE-46.63% 52W Range8.39 - 22.19 Perf YTD20.38%
Dividend Est.- P/FCF- EPS past 5Y-29.52% ROI-36.03% 52W High-20.95% Beta0.84
Dividend TTM- Quick Ratio13.43 Sales past 5Y0.00% Gross Margin- 52W Low109.08% ATR (14)0.91
Dividend Ex-Date- Current Ratio13.43 EPS Y/Y TTM-3.24% Oper. Margin0.00% RSI (14)45.79 Volatility4.64% 5.66%
Employees55 Debt/Eq0.27 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price25.75
Option/ShortYes / Yes LT Debt/Eq0.27 EPS Q/Q4.98% Payout- Rel Volume1.87 Prev Close17.24
Sales Surprise- EPS Surprise10.75% Sales Q/Q- EarningsMar 27 AMC Avg Volume220.44K Price17.54
SMA20-6.70% SMA500.34% SMA20034.04% Trades Volume405,133 Change1.74%
Date Action Analyst Rating Change Price Target Change
Feb-22-24Initiated Stifel Buy $40
Dec-08-23Initiated H.C. Wainwright Buy $27
Oct-08-21Initiated Canaccord Genuity Buy $50
Sep-07-21Initiated Jefferies Buy $48
Jul-29-21Initiated Cowen Outperform
Jul-27-21Initiated Needham Buy $50
Jan-28-21Reiterated H.C. Wainwright Buy $14 → $18
Dec-24-20Reiterated H.C. Wainwright Buy $11 → $14
May-11-20Resumed Craig Hallum Buy
Nov-20-18Initiated H.C. Wainwright Buy $36
Apr-04-24 07:05AM
Apr-01-24 01:38PM
Mar-28-24 06:51AM
Mar-27-24 08:53PM
04:01PM Loading…
Mar-21-24 11:17AM
Mar-20-24 07:05AM
Mar-06-24 07:05AM
Feb-28-24 07:05AM
Feb-22-24 04:05PM
Feb-20-24 07:05AM
Dec-06-23 08:30AM
Dec-01-23 11:02AM
Nov-22-23 08:05AM
10:50AM Loading…
Nov-14-23 10:50AM
Nov-13-23 09:41PM
Nov-06-23 07:30AM
Nov-01-23 07:05AM
Oct-18-23 09:15AM
Sep-21-23 04:43PM
Sep-07-23 04:05PM
Sep-06-23 07:10PM
Aug-22-23 04:05PM
Aug-11-23 05:58AM
Aug-10-23 04:04PM
Aug-03-23 07:30AM
08:00AM Loading…
Jul-31-23 08:00AM
Jul-27-23 06:51AM
Jun-20-23 09:02AM
May-24-23 08:00AM
May-16-23 06:26AM
May-15-23 04:00PM
May-12-23 06:15AM
May-08-23 05:30PM
Apr-18-23 01:30PM
Apr-12-23 08:00AM
Mar-27-23 02:43AM
Mar-24-23 07:07AM
Mar-23-23 04:00PM
Mar-16-23 08:00AM
Mar-15-23 07:35PM
Mar-01-23 08:00AM
Feb-17-23 05:07AM
Feb-16-23 08:00AM
Dec-18-22 04:38AM
Dec-15-22 05:59AM
Dec-12-22 07:30AM
Dec-09-22 08:40AM
Dec-07-22 04:00PM
Nov-22-22 07:30AM
Nov-10-22 04:30PM
Nov-03-22 08:50AM
Sep-14-22 09:00AM
Aug-15-22 09:39AM
Aug-11-22 04:00PM
Aug-04-22 08:15AM
Aug-03-22 10:15AM
Jul-18-22 06:31PM
Jun-15-22 09:55AM
May-30-22 09:55AM
May-26-22 07:30AM
May-16-22 04:00PM
May-11-22 09:28AM
May-09-22 07:30AM
Apr-05-22 07:30AM
Mar-23-22 04:00PM
Mar-16-22 07:30AM
Mar-02-22 07:30AM
Mar-01-22 07:02AM
Jan-18-22 12:39PM
Dec-10-21 09:30AM
Dec-02-21 08:30AM
Nov-29-21 05:00PM
Nov-15-21 08:00AM
Nov-09-21 05:30PM
Nov-08-21 04:00PM
Oct-29-21 09:00AM
Oct-18-21 04:09PM
Oct-14-21 02:08PM
Sep-02-21 07:42AM
Aug-09-21 04:00PM
Aug-05-21 08:00AM
Aug-02-21 07:30AM
Jul-08-21 04:15PM
Jun-30-21 09:06AM
Jun-29-21 11:11AM
Jun-28-21 11:30PM
Jun-09-21 09:10AM
May-10-21 04:00PM
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Buller Richard EDirectorFeb 21 '24Sale14.153504,9528,081Feb 23 04:43 PM
Buller Richard EDirectorDec 20 '23Sale14.373505,0308,431Dec 22 04:09 PM
Dalvey DavidDirectorDec 15 '23Sale14.572,94042,847225,000Dec 18 04:43 PM
Dalvey DavidDirectorDec 14 '23Sale14.755,00073,752227,940Dec 18 04:43 PM
Dalvey DavidDirectorDec 13 '23Sale14.505,00072,500232,940Dec 14 06:05 PM
Dalvey DavidDirectorDec 12 '23Sale14.612,06030,089237,940Dec 14 06:05 PM
Dalvey DavidDirectorDec 08 '23Sale15.005,00075,000240,000Dec 11 04:19 PM
Dalvey DavidDirectorDec 07 '23Sale14.855,00074,250245,000Dec 11 04:19 PM
Furcht LeoDirectorNov 28 '23Option Exercise1.6025040010,500Nov 30 04:12 PM
Buller Richard EDirectorOct 25 '23Sale10.233503,5808,781Oct 27 04:30 PM
Buller Richard EDirectorAug 30 '23Sale9.283503,2489,131Sep 01 04:07 PM
Buller Richard EDirectorAug 23 '23Sale9.823002,9469,481Aug 25 05:09 PM
Buller Richard EDirectorJun 23 '23Sale11.793003,5379,781Jun 27 04:11 PM
Buller Richard EDirectorMay 23 '23Sale11.107583210,081May 25 04:23 PM
Furcht LeoDirectorMay 22 '23Buy10.3210,000103,18710,250May 24 04:32 PM
Buller Richard EDirectorMay 22 '23Sale10.501001,05010,156May 23 04:12 PM
Buller Richard EDirectorMay 19 '23Sale9.852502,46210,256May 23 04:12 PM